A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN, Mercado M, Moerman-Herzog AM, Spencer HJ, Andrews-Collins NR, Hitt WC, Low GM, Manning NA, McKelvey SS, Smith D, Smith MV, Phillips AM, Quick CM, Jeffus SK, Hutchins LF, Nakagawa M.
Greenfield WW, et al. Among authors: manning na.
Oncoimmunology. 2015 May 27;4(10):e1031439. doi: 10.1080/2162402X.2015.1031439. eCollection 2015 Oct.
Oncoimmunology. 2015.
PMID: 26451301
Free PMC article.